| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | 0 |
Sells | $29,588,685 | 51 | 100 |
| Quart Barry D | director | 0 | $0 | 3 | $833,001 | $-833,001 |
| Megna Michael R | CHIEF ACCOUNTING OFFICER | 0 | $0 | 4 | $1.11M | $-1.11M |
| Paolini John F. | CHIEF MEDICAL OFFICER | 0 | $0 | 3 | $2.17M | $-2.17M |
| Moat Ross | CHIEF COMMERCIAL OFFICER | 0 | $0 | 6 | $5.4M | $-5.4M |
| Ragosa Mark | CHIEF FINANCIAL OFFICER | 0 | $0 | 12 | $5.67M | $-5.67M |
| Tessari Eben | CHIEF OPERATING OFFICER | 0 | $0 | 14 | $6.2M | $-6.2M |
| Patel Sanj K | CHAIRMAN & CEO | 0 | $0 | 9 | $8.21M | $-8.21M |
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Over the last 12 months, insiders at Kiniksa Pharmaceuticals, Ltd. have bought $0 and sold $29.59M worth of Kiniksa Pharmaceuticals, Ltd. stock.
On average, over the past 5 years, insiders at Kiniksa Pharmaceuticals, Ltd. have bought $0 and sold $12.12M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,686,704 shares for transaction amount of $31.99M was made by Flynn James E (10 percent owner) on 2018‑05‑29.
| 2025-06-16 | Sale | Tessari Eben | CHIEF OPERATING OFFICER | 17,300 0.0236% | $28.28 | $489,244 | -1.08% | |
| 2025-06-11 | Sale | Tessari Eben | CHIEF OPERATING OFFICER | 45,042 0.0623% | $30.51 | $1.37M | -6.80% | |
| 2025-06-11 | Sale | Quart Barry D | director | 12,336 0.017% | $30.39 | $374,891 | -6.80% | |
| 2025-06-10 | Sale | Tessari Eben | CHIEF OPERATING OFFICER | 15,506 0.0217% | $30.46 | $472,313 | -5.16% | |
| 2025-06-10 | Sale | Quart Barry D | director | 8,212 0.0115% | $30.36 | $249,316 | -5.16% | |
| 2025-06-09 | Sale | Tessari Eben | CHIEF OPERATING OFFICER | 10,319 0.0142% | $30.38 | $313,491 | -6.69% | |
| 2025-06-09 | Sale | Quart Barry D | director | 6,900 0.0094% | $30.26 | $208,794 | -6.69% | |
| 2025-06-03 | Sale | Megna Michael R | CHIEF ACCOUNTING OFFICER | 15,211 0.0206% | $28.75 | $437,316 | -2.40% | |
| 2025-06-03 | Sale | Ragosa Mark | CHIEF FINANCIAL OFFICER | 18,299 0.0248% | $28.80 | $527,011 | -2.40% | |
| 2025-06-03 | Sale | Moat Ross | CHIEF COMMERCIAL OFFICER | 27,594 0.0377% | $29.02 | $800,778 | -2.40% | |
| 2025-05-28 | Sale | Patel Sanj K | CHAIRMAN & CEO | 62,116 0.0853% | $27.33 | $1.7M | +4.11% | |
| 2025-05-27 | Sale | Patel Sanj K | CHAIRMAN & CEO | 19,317 0.027% | $27.01 | $521,752 | +6.98% | |
| 2025-05-23 | Sale | Patel Sanj K | CHAIRMAN & CEO | 4,837 0.0067% | $27.00 | $130,599 | +5.24% | |
| 2025-05-20 | Sale | Patel Sanj K | CHAIRMAN & CEO | 2,349 0.0033% | $27.02 | $63,470 | +5.25% | |
| 2025-05-19 | Sale | Tessari Eben | CHIEF OPERATING OFFICER | 12,000 0.0162% | $26.41 | $316,920 | +4.86% | |
| 2025-05-13 | Sale | Patel Sanj K | CHAIRMAN & CEO | 2,872 0.0042% | $27.03 | $77,630 | +9.10% | |
| 2025-05-09 | Sale | Patel Sanj K | CHAIRMAN & CEO | 6,029 0.0086% | $27.05 | $163,084 | +7.26% | |
| 2025-05-08 | Sale | Patel Sanj K | CHAIRMAN & CEO | 101 0.0001% | $27.00 | $2,727 | +4.42% | |
| 2025-05-07 | Sale | Paolini John F. | CHIEF MEDICAL OFFICER | 200 0.0003% | $27.00 | $5,400 | +4.15% | |
| 2025-05-07 | Sale | Megna Michael R | CHIEF ACCOUNTING OFFICER | 17,647 0.0241% | $26.69 | $470,998 | +4.15% |
| Patel Sanj K | CHAIRMAN & CEO | 96674 0.1325% | $2.78M | 1 | 18 | |
| Tessari Eben | CHIEF OPERATING OFFICER | 61563 0.0844% | $1.77M | 0 | 15 | |
| Paolini John F. | CHIEF MEDICAL OFFICER | 57403 0.0787% | $1.65M | 0 | 13 | |
| Megna Michael R | CHIEF ACCOUNTING OFFICER | 32546 0.0446% | $937,324.80 | 0 | 8 | |
| Ragosa Mark | CHIEF FINANCIAL OFFICER | 27009 0.037% | $777,859.20 | 0 | 13 | |
| Quart Barry D | director | 12546 0.0172% | $361,324.80 | 0 | 4 | |
| Moat Ross | CHIEF COMMERCIAL OFFICER | 9415 0.0129% | $271,152.00 | 0 | 6 | |
| BAKER BROS. ADVISORS LP | 2700597 3.7009% | $77.78M | 2 | 0 | +4.3% | |
| Cormorant Asset Management, LP | director | 900443 1.234% | $25.93M | 1 | 0 | +4.3% |
| Flynn James E | 10 percent owner | 843352 1.1557% | $24.29M | 1 | 0 | +4.3% |
| Beetham Thomas W. | EVP & Chief Legal Officer | 297523 0.4077% | $8.57M | 1 | 6 | |
| BOESS CARSTEN | 10 percent owner | 6392 0.0088% | $184,089.60 | 1 | 0 | |
| Heberlig Chris | Exec VP & CFO | 6392 0.0088% | $184,089.60 | 1 | 0 | |
| Mahoney Stephen F. | President & COO | 6392 0.0088% | $184,089.60 | 1 | 0 |
$66,492,695 | 135 | 27.65% | $2.45B | |
$193,151,375 | 134 | 8.18% | $1.92B | |
$1,376,668 | 53 | 18.46% | $2B | |
$5,066,938 | 27 | 26.38% | $2.5B | |
$150,253,463 | 26 | -52.83% | $2.02B | |
$174,105,409 | 15 | 10.88% | $2.5B | |
$154,554,190 | 14 | 29.60% | $2.27B | |
$137,027,226 | 13 | 28.32% | $1.9B | |
$1,248,715 | 10 | 5.66% | $2.09B | |
$45,445,266 | 9 | -24.96% | $1.98B | |
$55,713,031 | 8 | -0.36% | $2.56B | |
$25,073,947 | 7 | -5.99% | $1.99B | |
$24,000,085 | 4 | 33.26% | $2B | |
Kiniksa Pharmaceuticals, Ltd. (KNSA) | $142,493,653 | 3 | 4.30% | $2.1B |
$362,532 | 3 | -1.02% | $2.49B | |
$103,599,972 | 2 | -36.81% | $2.11B | |
$9,900,000 | 1 | -7.19% | $2.13B | |
$7,600,000 | 1 | -4.05% | $1.97B | |
$49,999,992 | 1 | 50.02% | $2.31B |
| Increased Positions | 100 | +55.56% | 9M | +22.06% |
| Decreased Positions | 79 | -43.89% | 7M | -17.91% |
| New Positions | 39 | New | 4M | New |
| Sold Out Positions | 22 | Sold Out | 2M | Sold Out |
| Total Postitions | 201 | +11.67% | 41M | +4.15% |
| Braidwell Lp | $95,460.00 | 8.22% | 3.45M | +557,934 | +19.28% | 2024-12-31 |
| Blackrock, Inc. | $94,914.00 | 8.17% | 3.43M | -139,164 | -3.9% | 2025-03-31 |
| Vanguard Group Inc | $88,687.00 | 7.64% | 3.21M | -90,759 | -2.75% | 2024-12-31 |
| Baker Bros. Advisors Lp | $77,927.00 | 6.71% | 2.82M | 0 | 0% | 2024-12-31 |
| Rubric Capital Management Lp | $72,418.00 | 6.24% | 2.62M | +200,000 | +8.27% | 2024-12-31 |
| Fairmount Funds Management Llc | $60,674.00 | 5.23% | 2.19M | -1M | -31.53% | 2024-12-31 |
| Hhlr Advisors, Ltd. | $43,760.00 | 3.77% | 1.58M | 0 | 0% | 2024-12-31 |
| Morgan Stanley | $41,136.00 | 3.54% | 1.49M | +462,276 | +45.08% | 2024-12-31 |
| Pictet Asset Management Holding Sa | $31,353.00 | 2.7% | 1.13M | 0 | 0% | 2025-03-31 |
| Nuveen Asset Management, Llc | $21,999.00 | 1.89% | 795,612 | +54,361 | +7.33% | 2024-12-31 |